Last updated: August 3, 2020

polyp_528-X-10E4-PGN-d35-1_v01-BD.jpg

HOWEVER

The real battle against cancer is fought by physicians and patients!

Our mission is simply to provide healthcare professionals

with innovative tools that are the most reliable and effective possible.

The hPG80 blood biomarker has now been shown to be both a major weak point of cancer and a fundamental target to providing physicians with multiple solutions, now and in the future * :

In cancer, hPG80 is overexpressed in the tumor and detectable in the patient’s blood[1]. 16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date[1].

  • Cancer stem cells express elevated levels of hPG80 (circulating progastrin)[2][3].

  • Secretion of hPG80 maintain tumor-initiating and self-renewal capabilities of cancer stem cells[3].

  • hPG80 is released from the tumor and becomes detectable in the blood across all stages[3][4].

  • Plasma hPG80 is elevated in a wide range of cancer patients[5]

hPG80 is produced by all cancer cells, but in quantities 100 to 1000 times higher by cancer stem cells[2], making hPG80 the only blood biomarker that gives information on tumor activity.

BIBLIOGRAPHY

[1]. You et al, EBioMedicine, 2020 Jan;51:102574

[2]. Giraud et al, Cancer Res, 2016;76(12):3618-28

[3]. Siddheshwar et al, Gut, 2001 Jan; 48(1): 47–52

[4]. Prieur et al, Clin Cancer Res. 2017;23(17):5267–5280

[5]. Konieczkowski et al, Cancer Cell, 2018 May 14;33(5):801-815

KEY FACTS

ecs-parralax-decode-lab_edited_edited.jp

CURRENT AND PROSPECTIVE

CLINICAL APPLICATIONS

CURRENT

FOLLOW UP

hPG80 measurement, and its trend, from simple blood samples, can help Physicians in the follow-up of patients, providing them with additional meaningful information on:

  • treatment efficacy,

  • risk of minimal residual disease,

  • risk of relapse.



     

CURRENT

DIAGNOSIS

The presence or absence of hPG80 in blood can also provide Physicians with an additional indicator of vigilance for earlier diagnosis, especially for at-risk populations and for cancers for which no biomarker exists.



 

PROSPECTIVE

OTHER USES

In addition, other potential uses for hPG80 are being investigated and will be available to physicians in a few years:

  • hPG80 neutralization has shown that it can lead to a new clinical approach to tumor reversion therapy that causes cancer cells to return to “normal”,
     

  • hPG80 can provide a major breakthrough in tumor localization by PET Scan imaging,
     

  • Finally, the robustness of its detection in blood makes it possible to envisage in the short term the production of a hPG80 rapid test providing physicians and health authorities with a new affordable and very minimally invasive tool that could help them in their early detection strategies.


     

NOW AVAILABLE TO PHYSICIANS

A NEW TOOL :

20200624-DxPG80-VUE-3D _v05.jpg

The blood test

for detection and measurement of the target hPG80

AVAILABLE ONLY ON MEDICAL PRESCRIPTION

Contact Us

 

IT'S TIME TO CONTROL CANCER

It has been shown that hPG80 (Circulating Progastrin) is produced by all cancer cells across all stages, but in quantities 100 to 1000 times higher by cancer stem cells which are considered to be primarily responsible for recurrence and metastasis. 

hPG80 is released from the tumor and becomes detectable in the blood, making hPG80 the only blood biomarker that not only detect the presence but also the activity of the tumor.

16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date.

Detection and assay of hPG80 can provide Physicians with new information that can help them:

  • Evaluate treatment efficacy,

  • Monitor risk of relapse,

  • Assess Minimal Residual Disease (MRD) risk,

  • Diagnose cancers which have no biomarker and for at-risk populations, in order to detect early enough the tumor, easily located in these populations.

ECS-Progastrin is a subsidiary of Progastrine Invest SCSp (Cancer Control Funding Fund)  11 côte d'Eich, L1450, Luxemburg City - Grand Duchy of Luxemburg

MAINS LOCATIONS AND OFFICES:

  • LUXEMBURG

  • SWITZERLAND

  • FRANCE

  • UNITED ARAB EMIRATES

  • UNITED STATES OF AMERICA

MAINS COMPANIES:

  • ECS PROGASTRIN

  • ECS PROGASTRIN LAB

  • PROGASTRINE ET CANCERS

  • EUROBIODEV

  • PROGASTRIN MANUFACTURING

Progastrine Invest SCSp and its subsidiaries:

  • focus on innovation in cancer diagnosis, localization, follow-up and treatment,

  • hold the rights to the first hPG80 (Circulating Progastrin) assay which is now available,

  • hold the rights to the cancer therapy project with an anti-hPG80 antibody.

 

For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.

 

The management of Progastrine Invest SCSp subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2015-2020 ECS-Progastrin ® . All rights reserved